Popular hospital rating systems differ in terms of quality and safety measures

Four hospital rating systems aimed at consumers vary in their conclusions on how facilities are performing because each uses its own methodology. The findings were published in Health Affairs.

The authors examined ratings released in 2012 and 2013 from U.S. News & World Report, HealthGrades, the LeapFrog group and Consumer Reports. The latter two are non-profit organizations, while the other two are for-profit. The hospitals did not pay to get rated.

Consumer Reports does not allow hospitals to use the ratings in promotional materials, while the other three organizations allow hospitals to pay a fee and then use the ratings in their advertisements.

In all, 83 hospitals were rated by all four systems, but no hospital received high performer status in all four ratings system. Further, 10 percent of the 844 hospitals receiving a high performer grade in one system were rated as a high performer in any other system.

Each of the ratings systems has different eligibility criteria and measurements.

The authors noted a few limitations, including that they used only one round of ratings for each of the systems, evaluated only four rating systems, had to define high-performing and low-performing in rating systems that had no formal definitions and none of the rating systems defined what constituted a hospital.

“The complexity and opacity of the ratings is likely to cause confusion instead of driving patients and purchasers to higher-quality, safer care,” the authors wrote. “Given our findings, maximum transparency regarding each rating’s measures and methods is needed to help stakeholders understand any individual rating and to compare across ratings. There is also a need to better understand whether the disagreement in rankings serves as a motivation for hospitals to provide more complete information to consumers.”

Read the Health Affairs study here.

Tim Casey,

Executive Editor

Tim Casey joined TriMed Media Group in 2015 as Executive Editor. For the previous four years, he worked as an editor and writer for HMP Communications, primarily focused on covering managed care issues and reporting from medical and health care conferences. He was also a staff reporter at the Sacramento Bee for more than four years covering professional, college and high school sports. He earned his undergraduate degree in psychology from the University of Notre Dame and his MBA degree from Georgetown University.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.